ArticleHeliyon2024

STX4 as a potential biomarker for predicting prognosis and guiding clinical treatment decisions in clear cell renal cell carcinoma.

Kai Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.